https://scholars.lib.ntu.edu.tw/handle/123456789/485649
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Feng-Ming Hsu | en_US |
dc.contributor.author | Hou W.-H. | en_US |
dc.contributor.author | CHAO-YUAN HUANG | en_US |
dc.contributor.author | CHIA-CHUN WANG | en_US |
dc.contributor.author | CHIAO-LING TSAI | en_US |
dc.contributor.author | YU-CHIEH TSAI | en_US |
dc.contributor.author | HONG-JENG YU | en_US |
dc.contributor.author | YEONG-SHIAU PU | en_US |
dc.contributor.author | CHIA-HSIEN CHENG | en_US |
dc.creator | Hsu F.-M.;Hou W.-H.;Huang C.-Y.;Wang C.-C.;Tsai C.-L.;Tsai Y.-C.;Yu H.-J.;Pu Y.-S.;Chia-Hsien Cheng | - |
dc.date.accessioned | 2020-04-27T08:45:11Z | - |
dc.date.available | 2020-04-27T08:45:11Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 0742-0528 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84961211381&doi=10.3109%2f07420528.2015.1130049&partnerID=40&md5=e594538d008a9530c2f73251a04345aa | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/485649 | - |
dc.description.abstract | This retrospective study tested the hypothesis that disease control and treatment-related toxicity in patients undergoing high-dose radiotherapy (HDRT) for prostate cancer varies in a circadian manner. Patients with localized prostate adenocarcinoma receiving HDRT (median 78 Gy) to the prostate and involved seminal vesicle(s) without elective pelvic irradiation were divided into a daytime treatment (before 5 PM) group (n = 267) and evening treatment (after 5 PM) group (n = 142). Biochemical failure (Phoenix definition), acute and late gastrointestinal (GI) and genitourinary toxicities (Common Terminology Criteria for Adverse Events version 4), biochemical failure-free survival (BFFS) and freedom from late toxicity were assessed. Analyses were performed by binary logistic regression and Cox proportional hazard regression. The median follow-up was 68 months, and 75% of patients were ?70 years old. Evening HDRT was significantly associated with worse freedom from ?grade 2 late GI complications (hazard ratio = 2.96; p < 0.001). The detrimental effect of evening HDRT was significant in patients older than 70 years old (p < 0.001) but not in younger patients (p = 0.63). In a subgroup of propensity score-matched cohort with T2b-T3 disease (n = 154), the 5-year BFFS was worse in the evening group than the daytime group (72% vs. 85%, hazard ratio = 1.95, p = 0.05). Our study indicates that evening HDRT may lead to more GI complications, especially in older patients, and worse BFFS in patients with T2b-T3 disease. ? 2016 Taylor & Francis. | - |
dc.publisher | Taylor and Francis Ltd | - |
dc.relation.ispartof | Chronobiology International | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | adenocarcinoma; aged; circadian rhythm; disease free survival; female; human; male; metabolism; middle aged; physiology; prostate; Prostatic Neoplasms; retrospective study; treatment outcome; very elderly; Adenocarcinoma; Aged; Aged, 80 and over; Circadian Rhythm; Disease-Free Survival; Female; Humans; Male; Middle Aged; Prostate; Prostatic Neoplasms; Retrospective Studies; Treatment Outcome | - |
dc.title | Differences in toxicity and outcome associated with circadian variations between patients undergoing daytime and evening radiotherapy for prostate adenocarcinoma | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.3109/07420528.2015.1130049 | - |
dc.identifier.pmid | 26818960 | - |
dc.identifier.scopus | 2-s2.0-84961211381 | - |
dc.relation.pages | 210-219 | - |
dc.relation.journalvolume | 33 | - |
dc.relation.journalissue | 2 | - |
item.fulltext | no fulltext | - |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Urology | - |
crisitem.author.dept | Urology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Urology | - |
crisitem.author.dept | Urology-NTUH | - |
crisitem.author.dept | Surgical Oncology-NTUCC | - |
crisitem.author.dept | Urology-NTUHBP | - |
crisitem.author.dept | Oncology | - |
crisitem.author.orcid | 0000-0001-9943-6039 | - |
crisitem.author.orcid | 0000-0002-9322-6062 | - |
crisitem.author.orcid | 0000-0002-3337-0652 | - |
crisitem.author.orcid | 0000-0002-9285-7655 | - |
crisitem.author.orcid | 0000-0003-3287-5736 | - |
crisitem.author.orcid | 0000-0002-2859-3966 | - |
crisitem.author.orcid | 0000-0002-2007-0220 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | NTU BioMedical Park Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。